Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Complete title: A Feasibility Study of 'Early' Allogenic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasm

Research Study Number 9567
Principal Investigator Mary-Elizabeth Percival
Phase Pilot

Research Study Description

This clinical trial studies how well early stem cell transplantation works in treating patients with high-grade myeloid neoplasms that has come back after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as filgrastim, cladribine, cytarabine and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor peripheral blood cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient?s immune cells and help destroy any remaining cancer cells. Early stem cell transplantation may result in more successful treatment for patients with high-grade myeloid neoplasms.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years to 75 Years (Adult, Senior)

Sexes Eligible for Study: All


- Relapsed or refractory high-grade myeloid neoplasms, defined as having a blast count of >= 10% blasts at initial diagnosis; examples include excess blasts (EB)-2, with >= 10% blasts at initial diagnosis, acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML-2); standard definitions of relapse will apply (i.e., characterized by >= 5% abnormal blasts as assessed by multiparameter flow cytometry or morphologic examination; peripheral blood blasts; or extramedullary granulocytic sarcoma, per European LeukemiaNet [ELN] 2017 guidelines); bone marrow aspirate/biopsy will be accepted if performed outside University of Washington/Fred Hutchinson Cancer Research Center (UW/FHCRC); determination of disease status should occur within 30 days of signing informed consent

-- * R/R high-grade myeloid neoplasm following intensive induction chemotherapy; relapsed high-grade myeloid neoplasm: patients will be classified as relapsed if they have >= 5% blasts after being in a complete remission (CR) following treatment for high-grade myeloid neoplasm; refractory high-grade myeloid neoplasm: patients may be classified as refractory if they have received at least one prior cycle of induction chemotherapy, whether with cladribine cytarabine mitoxantrone (GCLAM) or another regimen

--- ** Patients may have received up to two courses of intensive induction chemotherapy during initial treatment prior to enrollment on this protocol; for example, patients who have received two courses of granulocyte colony stimulating factor (G-CSF) GCLAM (or similar) chemotherapy, with most recent high-dose cytarabine-containing chemotherapy > 6 months ago and CR lasting > 6 months, will be eligible for this protocol; regimens ?similar to GCLAM? Would include cytarabine at doses of 1g/m^2 for at least 5 doses; examples of regimens ?similar to GCLAM? Would be GCLA, fludarabine cytarabine granulocyte (FLAG), and FLAG-idarubicin (ida); however, patients who received more than two courses of GCLAM (or similar) chemotherapy, or patients who received two courses of GCLAM and had CR lasting < 6 months, would not be eligible

-- * R/R high-grade myeloid neoplasm following less intensive induction chemotherapy. Patients who have received at least three cycles of treatment with a hypomethylating agent (HMA; such as azacitidine or decitabine) and still have >= 10% blasts will be eligible for the study (they will be considered refractory); similarly, patients who have received three or more cycles of HMA therapy who have had a response (e.g., achieving CR with < 5% blasts), but who then progress using standard definitions of relapse, will also be eligible (they will be considered relapsed)

- Potentially eligible for reduced intensity conditioning based on known organ function (formal organ function testing may occur after consent)

- Caregiver capable of providing post-HCT care

- Written informed consent


- Matched related or unrelated (8/8 matched at human leukocyte antigen [HLA]-A, -B, -C, -DRB1) donor according to institutional standards

- Caregiver capable of providing post-HCT care, who will be present once induction therapy with filgrastim, cladribine, cytarabine, mitoxantrone hydrochloride (GCLAM) begins

- Written informed consent for transplant

- Either bone marrow or peripheral blood is allowed

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)


- Prior allogeneic HCT

- More than two prior courses of induction chemotherapy

- Relapse after minimal residual disease (MRD)-negative CR within 3 months of most recent GCLAM chemotherapy

- Low likelihood of being eligible for reduced intensity conditioning HCT based on known information

-- * Cardiac ejection fraction < 40% or symptomatic coronary artery disease or uncontrolled arrhythmia

-- * Diffusing capacity of the lungs for carbon monoxide (DLCOc) < 40% or forced expiratory volume in 1 second (FEV1) < 50%

-- * Estimated glomerular filtration rate (GFR) < 40 ml/min

-- * Need for supplemental oxygen

-- * Direct bilirubin or alanine aminotransferase (ALT) > 2 x upper limit of normal, unless these abnormalities are thought to be related to Gilbert?s disease or leukemic infiltration of hepatic parenchyma

- Known human immunodeficiency virus (HIV) positivity

- Pregnant or nursing (to be confirmed with quantitative human chorionic gonadotropin [HCG] testing)

- Invasive solid tumor within 5 years; non-melanoma skin cancer or in situ malignancies are allowed


- Donor specific antibodies against donor HLA?DQ or ?DP

- Active bacterial, fungal or viral infections unresponsive to medical therapy

- Active leukemia in the central nervous system (CNS)

- HIV positive

- Cardiac ejection fraction < 40% or symptomatic coronary artery disease or uncontrolled arrhythmia

- DLCOc < 40% or FEV1 < 50%

- Estimated GFR < 40 ml/min

- Need for supplemental oxygen

- Direct bilirubin or ALT > 2 x upper limit of normal, unless these abnormalities are thought to be related to Gilbert?s disease or leukemic infiltration of hepatic parenchyma

Other exclusion criteria may apply.

Research Study Number 9567
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Myelodysplastic Syndromes (MDS); Leukemia, Myeloid; Hematopoietic Cell Transplantation (HCT); Preleukemia; Bone Marrow Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials